- Home
- BRNS vs RAND Comparison
BRNS vs RAND Comparison
Compare BRNS & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- RAND
- Stock Information
- Founded
- BRNS 2016
- RAND 1969
- Country
- BRNS United Kingdom
- RAND United States
- Employees
- BRNS N/A
- RAND N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- BRNS Health Care
- RAND Finance
- Exchange
- BRNS Nasdaq
- RAND Nasdaq
- Market Cap
- BRNS 48.3M
- RAND 54.4M
- IPO Year
- BRNS 2021
- RAND N/A
- Fundamental
- Price
- BRNS $1.07
- RAND $15.21
- Analyst Decision
- BRNS Strong Buy
- RAND
- Analyst Count
- BRNS 1
- RAND 0
- Target Price
- BRNS $3.00
- RAND N/A
- AVG Volume (30 Days)
- BRNS 42.9K
- RAND 5.0K
- Earning Date
- BRNS 11-05-2025
- RAND 11-05-2025
- Dividend Yield
- BRNS N/A
- RAND 11.03%
- EPS Growth
- BRNS N/A
- RAND N/A
- EPS
- BRNS N/A
- RAND N/A
- Revenue
- BRNS $14,969,000.00
- RAND $7,966,118.00
- Revenue This Year
- BRNS N/A
- RAND N/A
- Revenue Next Year
- BRNS N/A
- RAND N/A
- P/E Ratio
- BRNS N/A
- RAND N/A
- Revenue Growth
- BRNS 1766.46
- RAND 1.16
- 52 Week Low
- BRNS $0.64
- RAND $13.82
- 52 Week High
- BRNS $2.92
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- BRNS 41.80
- RAND 46.04
- Support Level
- BRNS $1.08
- RAND $14.50
- Resistance Level
- BRNS $1.20
- RAND $15.25
- Average True Range (ATR)
- BRNS 0.10
- RAND 0.66
- MACD
- BRNS -0.01
- RAND 0.03
- Stochastic Oscillator
- BRNS 22.16
- RAND 31.70
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.